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	 	What	is	the	best	treatment	
for	impetigo?
EvidEncE-basEd answEr
A	 Although	 evidence is lack- ing to	support	a	single	best	 treat-
ment	 for	 impetigo,	 topical	 mupirocin,	
fusidic	 acid,	 gentamicin,	 and	 retapamu-
lin	 are	 all	 at	 least	 20%	 more	 likely	 than	
placebo	 to	 produce	 cure	 or	 improvement	
(strength	 of	 recommendation	 [SOR]:	 a,	
meta-analysis	of	randomized	controlled	tri-
als	[RCTs]	and	a	single	RCT	of	retapamulin).	
Topical	bacitracin	and	fusidic	acid	are	
15%	 more	 likely	 than	 disinfectant	 solu-
tions	to	cure	or	improve	impetigo	(SOR:	a,	
systematic	review	of	RCTs).	
Oral	antibiotics	may	be	as	effective	as	
topical	antibiotics	(SOR:	b,	RCTs	with	dif-
ferent	results).
Evidence summary 
Most	data	on	the	effectiveness	of	topical	an-
tibiotics	focus	on	bacitracin,	fusidic	acid	(not	
available	 in	 the	United	States),	and	mupiro-
cin.	Retapamulin	1%	ointment,	a	topical	anti-
biotic	in	the	pleuromutilin	class,	is	approved	
by	 the	 US	 Food	 and	 Drug	 Administration	
(FDA)	 for	 use	 in	 adults	 and	 children	 older	
than	 9	 months	 to	 treat	 impetigo	 caused	 by	
methicillin-susceptible	 Staphylococcus au-
reus	and	Streptococcus pyogenes.1		
topical antibiotics outperform placebo 
A	2003	meta-analysis	of	 16	 studies	 (1944	pa-
tients)	 evaluated	 treatments	 for	 impetigo	 in	
both	 adults	 and	 children.2	 Investigators	 con-
ducted	most	 of	 the	 studies	 in	outpatient	 set-
tings	 in	 the	 United	 States,	 United	 Kingdom,	
Northern	Europe,	and	Canada.	They	expressed	
outcomes	in	terms	of	cure	or	clinical	improve-
ment	within	7	to	14	days	of	starting	treatment.	
Topical	agents,	including	mupirocin,	fu-
sidic	acid,	and	gentamicin,	resulted	in	cure	or	
improvement	in	more	patients	at	7	to	14	days	
than	placebo	(absolute	benefit	increase=20%;	
number	needed	to	treat	[NNT]=5;	95%	confi-
dence	interval	[CI],	1.49-4.86).	Definitions	of	
cure	 or	 improvement	 varied	 among	 the	 in-
cluded	studies,	however.	
A	2012	Cochrane	review	of	various	inter-
ventions	included	68	RCTs	with	a	total	of	5708	
participants,	primarily	from	pediatric	or	der-
matology	hospital	outpatient	clinics	in	North	
America	and	Europe.3	Clinical	cure	(defined	
as	 clearance	 of	 crusts,	 blisters,	 and	 redness	
as	determined	by	 investigators)	or	 improve-
ment	at	one	week	were	the	primary	outcomes	
(tABLE).3,4		Mupirocin	(relative	risk	[RR]=2.21;	
95%	CI,	1.16-3.13),	fusidic	acid	(RR=4.42;	95%	
CI,	 2.39-8.17),	 and	 retapamulin	 (RR=1.64;	
95%	 CI,	 1.30-2.07)	 all	 demonstrated	 higher	
rates	of	cure	or	improvement	than	placebo.
Retapamulin produces greater clinical 
response than placebo in an RCt 
A	 2008	 randomized,	 double-blind,	 multi-
center,	 industry-funded,	 placebo-controlled	
trial	 of	 213	 patients	 evaluated	 the	 effective-
ness	 of	 retapamulin	 to	 treat	 uncomplicated	
impetigo	with	an	outcome	of	clinical	response	
at	 7	 days.4	 Clinical	 response	was	 defined	 as	
total	absence	of	lesions,	drying	of	treated	le-
sions	 without	 crusts	 or	 erythema,	 decrease	
in	the	size	of	the	affected	area	or	decrease	in	
the	number	of	lesions.	Retapamulin	ointment	
produced	 a	 higher	 rate	 of	 clinical	 response	
than	placebo	(absolute	risk	reduction=33.5%;	
95%	CI,	20.5-46.5;	NNT=3,	P<.001).
coNTINuEd
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tABLE
How	well	do	impetigo	treatments	work?3,4
comparison Number of patients arr for cure or  
improvement
NNT cost of treatment*
Topical antibiotics vs 
placebo
575 41.2% 2
retapamulin vs placebo 213 33.5% 3 retapamulin 1% ointment 
(15 g): $130.12
Topical antibiotics vs 
disinfectant solution
292 11.4% 9
mupirocin vs fusidic acid 440 NS NS mupirocin ointment 2%  
(22 g): $42.75
Fusidic acid is not available 
in the united States
mupirocin vs oral 
erythromycin
581 5.1% 20 Erythromycin 100 tabs: 
$295.01 (250 mg),  
$314.23 (333 mg), $338.93 
(500 mg)
Erythromycin ethylsuccinate 
solution (100 ml):  
$170.50 (200 mg/5 ml), 
$218.14 (400 mg/5 ml) 
mupirocin vs dicloxacillin 53 NS NS dicloxacillin 100 tabs  
(250 mg): $66
mupirocin vs ampicillin 13 NS NS ampicillin 100 tabs  
(500 mg): $39.88
ampicillin suspension  
100 ml: $9.54 (125 mg/ 
5 ml), $14.08 (250 mg/5 ml)
Bacitracin vs oral 
erythromycin
30 NS NS Bacitracin ointment  
500 units/g (28.4 g): $3.47 
Bacitracin vs penicillin 34 NS NS Penicillin V oral 100 tabs 
(500 mg): $77.77
Penicillin V suspension  
100 ml: $3.84 (125 mg/ 
5 ml), $4.31 (250 mg/5 ml)
cephalexin vs bacitracin 19 56.7% 2 cephalexin 100 tabs  
(500 mg): $526.13
cephalexin oral suspension 
100 ml: $8.93 (125 mg/ 
5 ml), $18.90 (250 mg/ 
5 ml)
Erythromycin vs penicillin 79 22.4% 4 See above
cloxacillin vs penicillin 166 35.9% 3 cloxacillin is not available in 
the united States
arr, absolute risk reduction; NNT, number needed to treat; NS, not significant.
*cost data obtained from medi-Span at www.uptodate.com. accessed december 5, 2013.
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topical antibiotics work slightly better  
than disinfectant solutions
In	a	pooled	analysis	from	the	2012	Cochrane	
review,	 topical	 bacitracin	 and	 fusidic	 acid	
demonstrated	 slightly	 higher	 rates	 of	 cure	
or	 improvement	 than	 disinfectant	 solutions	
(RR=1.15;	95%	CI,	1.01-1.32).3
Oral antibiotics may work as well as,  
or better than, topicals
The	2012	Cochrane	 review	 found	better	 rates	
of	 cure	 or	 improvement	 for	 topical	 mupiro-
cin	 than	oral	 erythromycin	 (RR=1.07;	95%	CI,	
1.01-1.13).3	 Investigators	 noted	 no	 significant	
differences	 between	 topical	 mupirocin	 and	
bacitracin	and	oral	antibiotics	other	than	eryth-
romycin,	although	 in	one	 small	 study	 (10	pa-
tients),	oral	cephalexin	resulted	in	a	higher	rate	
of	cure	or	improvement	than	topical	bacitracin	
(absolute	risk	reduction	[ARR]=56.7%;	NNT=2).	
Studies	 comparing	 oral	 antibiotics	
found	 that	 both	 erythromycin	 and	 cloxacil-
lin	 (not	 available	 in	 the	 United	 States)	 pro-
duced	 higher	 rates	 of	 cure	 or	 improvement	
than	penicillin	(erythromycin,	RR=1.29;	95%	
CI,	 1.07-1.56;	 cloxacillin,	 RR=1.14;	 95%	 CI,	
0.80-1.62).
Recommendations
The	 Infectious	 Diseases	 Society	 of	 America	
recommends	 topical	 mupirocin	 as	 first-line	
therapy	 for	 impetigo,	 although	 resistance	 to	
the	 drug	 exists.	 Patients	 with	 numerous	 le-
sions	or	who	fail	 to	respond	to	topical	 treat-
ment	should	be	 treated	with	oral	antibiotics	
active	against S pyogenes and	S aureus.	Rec-
ommended	oral	 antibiotics	 include	dicloxa-
cillin,	 amoxicillin/clavulanate,	 cephalexin,	
erythromycin,	and	clindamycin.5																																			JFP
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